Suppr超能文献

人体肥胖中的肠道微生物失调:减重手术的影响。

Gut Microbiota Dysbiosis in Human Obesity: Impact of Bariatric Surgery.

机构信息

INSERM, NutriOmics Research Unit, Sorbonne Université, Paris, France.

Assistance Publique Hôpitaux de Paris, Nutrition Departement, Pitié-Salpêtrière Hospital, Sorbonne Université, 47-83 bd de l'Hôpital, 75013, Paris, France.

出版信息

Curr Obes Rep. 2019 Sep;8(3):229-242. doi: 10.1007/s13679-019-00351-3.

Abstract

PURPOSE OF REVIEW

In this review, we summarize what is currently described in terms of gut microbiota (GM) dysbiosis modification post-bariatric surgery (BS) and their link with BS-induced clinical improvement. We also discuss how the major inter-individual variability in terms of GM changes could impact the clinical improvements seen in patients.

RECENT FINDINGS

The persisting increase in severe obesity prevalence has led to the subsequent burst in BS number. Indeed, it is to date the best treatment option to induce major and sustainable weight loss and metabolic improvement in these patients. During obesity, the gut microbiota displays distinctive features such as low microbial gene richness and compositional and functional alterations (termed dysbiosis) which have been associated with low-grade inflammation, increased body weight and fat mass, as well as type-2 diabetes. Interestingly, GM changes post-BS is currently being proposed as one the many mechanism explaining BS beneficial clinical outcomes. BS enables partial rescue of GM dysbiosis observed during obesity. Some of the GM characteristics modified post-BS (composition in terms of bacteria and functions) are linked to BS beneficial outcomes such as weight loss or metabolic improvements. Nevertheless, the changes in GM post-BS display major variability from one patient to the other. As such, further large sample size studies associated with GM transfer studies in animals are still needed to completely decipher the role of GM in the clinical improvements observed post-surgery.

摘要

目的综述

在这篇综述中,我们总结了目前关于减重手术后肠道微生物群(GM)失调改变及其与 BS 诱导的临床改善的联系。我们还讨论了 GM 变化的个体间主要变异性如何影响患者的临床改善。

最近的发现

严重肥胖患病率的持续增加导致 BS 数量的激增。事实上,BS 是迄今为止诱导这些患者体重显著和持续减轻以及代谢改善的最佳治疗选择。在肥胖期间,肠道微生物群表现出独特的特征,例如微生物基因丰富度低,组成和功能改变(称为失调),这与低度炎症、体重增加和体脂增加以及 2 型糖尿病有关。有趣的是,GM 变化被认为是解释 BS 有益临床结果的众多机制之一。BS 使肥胖期间观察到的 GM 失调部分得到恢复。BS 后改变的 GM 特征(细菌组成和功能)与 BS 有益结果(如体重减轻或代谢改善)有关。然而,BS 后 GM 的变化在个体之间存在很大的可变性。因此,仍然需要进行更大的样本量研究,并结合 GM 在动物中的转移研究,以完全阐明 GM 在术后观察到的临床改善中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验